Open an account

Bio Rad Laboratories

BIO · NYSE

$354.50+$1.68 (+0.48%)TodayMarket closed ·
Prev close $352.82

About BIO

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Employees
7,450
Headquarters
Hercules, California
Listed
Mar 17, 1980
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
bio-rad.com

BIO key statistics

Market cap
9.48B
Price-earnings ratio
44.16
Dividend yield
—
Average volume
245.10K
Volume
142.34K
Open price
$352.08
High today
$356.93
Low today
$350.49
52 Week high
$396.23
52 Week low
$236.73

Bio Rad Laboratories (BIO) at a glance

As of Oct 20, 2026, Bio Rad Laboratories (BIO) shares are priced at $354.50, giving the company a market cap of 9.48B and a price-to-earnings ratio of 44.16.

Today the stock has traded between $350.49 and $356.93. The current price is 1.1% above the day's low and 0.7% below its high.

Volume so far is 142.34K shares, below the average of 245.10K shares a day.

Over the past year Bio Rad Laboratories has ranged from $236.73 to $396.23, and now sits 74% of the way up that range.

Bio Rad Laboratories met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $2.62 per share against an estimate of $1.77.

The average analyst price target is $359.55, 1.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

20%of 5 analyst ratings say Buy
  • Buy20.0%
  • Hold80.0%
  • Sell0.0%
Price target · 4 analystsAvg $359.55
Low
$318.15
Now
$354.50
High
$409.50

BIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 37.4% on average.

  1. Q3 FY24: reported $2.01 per share against an estimate of $1.17
  2. Q4 FY24: reported $2.90 per share against an estimate of $2.90
  3. Q1 FY25: reported $2.54 per share against an estimate of $1.83
  4. Q2 FY25: reported $2.61 per share against an estimate of $1.75
  5. Q3 FY25: reported $2.26 per share against an estimate of $1.95
  6. Q4 FY25: reported $2.51 per share against an estimate of $2.73
  7. Q1 FY26: reported $1.89 per share against an estimate of $2.00
  8. Q2 FY26: reported $2.62 per share against an estimate of $1.77

BIO news

  • Press releaseBusiness Wire

    Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • Press releaseBusiness Wire

    Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

  • Press releaseBusiness Wire

    Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

  • Press releaseGlobe Newswire

    IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

  • Press releaseBusiness Wire

    Bio-Rad Reports Second-Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

  • Vandana Singh

    Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories

  • Piero Cingari

    Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today

Similar companies

Companies in the same industry as Bio Rad Laboratories

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.